Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Genetic Variant of TLR6 Predicts HBsAg Decline After Pegylated Interferon-Alpha Treatment in HBeAg-Positive Chronic Hepatitis B.

Journal of medical virology - 1 Mar 2026

Zeng Wanting, Wang Jialin, Liang Xinghe, Hou Jia, Chen Jianjun, Pan Xinghua, Zhou Bing, Hou Jinlin, Jiang De-Ke

Abstract excerpt

Although toll-like receptor 6 (TLR6) plays an important role in innate immunity and host antiviral responses, its impact on pegylated interferon-alpha (PegIFNα) treatment efficacy in chronic hepatitis B (CHB) remains unclear. We aimed to investigate whether genetic variations of TLR6 are associated with the response to PegIFNα treatment. This study included 945 HBeAg-positive CHB patients treated with PegIFNα for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Hepatitis B, Chronic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hepatitis B e Antigens

Share to Hepatitis B Surface Antigens

Share to Interferon-alpha

Share to Polyethylene Glycols

Share to Polymorphism, Single Nucleotide

Share to Treatment Outcome

Source

Identifiers

PMID: 41823038
DOI: 10.1002/jmv.70872

Genes

TLR6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Genetic Variant of TLR6 Predicts HBsAg Decline After Pegylated Interferon-Alpha Treatment in HBeAg-Positive Chronic Hepatitis B.PMID 41823038Read ↗

CXCR7 genetic variant predicts treatment response of pegylated-interferon α in HBeAg-positive chronic hepatitis B patients.Semantic proximity Read ↗

Genetic polymorphisms of interleukin-6 modulate fibrosis progression in mild chronic hepatitis C.Semantic proximity Read ↗

A novel TRIM22 gene polymorphism promotes the response to PegIFNα therapy through cytokine-cytokine receptor interaction signaling pathway in chronic hepatitis B.Semantic proximity Read ↗

IFNL4 rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in IFN-treated HBeAg-negative chronic hepatitis B patients.Semantic proximity Read ↗

Higher TP53BP2 expression is associated with HBsAg loss in peginterferon-α-treated patients with chronic hepatitis BSemantic proximity Read ↗

Role of TLRs and IL-6 in the outcome of chronic hepatitis C treatment in Tunisian population.Semantic proximity Read ↗

Toll- like receptor 2 polymorphism and IL-6 profile in relation to disease progression in chronic HBV infection: a case control study in Egyptian patients.Semantic proximity Read ↗

Hepatitis b infection: progress in identifying patients most likely to respond to peginterferon alfa.Semantic proximity Read ↗

IL6 gene allele-specific C/EBPα-binding activity affects the development of HBV infection through modulation of Th17/Treg balance.Semantic proximity Read ↗

TRIM26 inhibits hepatitis B virus replication by promoting HBx degradation and TRIM26 genetic polymorphism predicts PegIFNα treatment response of HBeAg‐positive chronic hepatitis B PatientsSemantic proximity Read ↗

ZNF350 gene polymorphisms promote the response to Peg-IFNα therapy through JAK-STAT signaling pathway in patients with chronic hepatitis B.Semantic proximity Read ↗

Longitudinal characterization of phenotypic profile of T cells in chronic hepatitis B identifies immune markers predicting HBsAg lossSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.